Reasons for switching clotting factor concentrates
| Improved safety (real or perceived) |
| Less risk of infection |
| Less inhibitor risk |
| Fewer side-effects (eg, allergic reactions) |
| Newer generation of product |
| Price |
| National contracting |
| Volume of final product |
| Mixing and administration device |
| Storage advantage |
| Patient/family preference |
| Longer half-life |
| Participation in a clinical trial of a new product/formulation |
| Research study participation that specifies product to be used |
| Improved safety (real or perceived) |
| Less risk of infection |
| Less inhibitor risk |
| Fewer side-effects (eg, allergic reactions) |
| Newer generation of product |
| Price |
| National contracting |
| Volume of final product |
| Mixing and administration device |
| Storage advantage |
| Patient/family preference |
| Longer half-life |
| Participation in a clinical trial of a new product/formulation |
| Research study participation that specifies product to be used |